https://www.trevena.com/ https://www.trevena.com/about https://www.trevena.com/pipeline https://www.trevena.com/pipeline/trv045 https://www.trevena.com/pipeline/trv250 https://www.trevena.com/pipeline/trv734 https://www.trevena.com/medical-affairs/investigator-initiated-trials https://www.trevena.com/publications https://www.trevena.com/investors https://www.trevena.com/investors/press-releases https://www.trevena.com/investors/events-presentations/ir-calendar https://www.trevena.com/investors/events-presentations/presentations https://www.trevena.com/investors/financial-information https://www.trevena.com/investors/financial-information/all-sec-filings https://www.trevena.com/investors/financial-information/annual-reports https://www.trevena.com/investors/financial-information/quarterly-reports https://www.trevena.com/investors/financial-information/section-16-filings https://www.trevena.com/investors/stock-information/quote https://www.trevena.com/investors/stock-information/analyst-coverage https://www.trevena.com/investors/investor-resources/email-alerts https://www.trevena.com/investors/investor-resources/contacts https://www.trevena.com/investors/investor-resources/faq https://www.trevena.com/investors/corporate-governance/governance-documents https://www.trevena.com/careers https://www.trevena.com/contact https://www.trevena.com/contact/contact-medical-information https://www.trevena.com/investors/press-releases/detail/346/trevena-reports-third-quarter-2024-results-and-provides-business-update https://www.trevena.com/investors/press-releases/detail/345/trevena-announces-receipt-of-nasdaq-delisting-notification https://www.trevena.com/investors/press-releases/detail/344/trevena-announces-reverse-stock-split https://www.trevena.com/investors/press-releases/detail/343/trevena-reports-second-quarter-2024-results-and-provides-business-update https://www.trevena.com/investors/press-releases/detail/342/trevena-announces-2m-non-dilutive-financing-tranche-and-reduction-in-outstanding-liabilities-in-connection-with-existing-ex-us-royalty-financing https://www.trevena.com/investors/press-releases/detail/341/trevena-announces-preclinical-trv045-data-providing-insight-into-novel-mechanism-of-analgesic-effect-in-chronic-neuropathic-pain-model-and-demonstrating-statistically-significant-anti-seizure-activity-in-epilepsy-models https://www.trevena.com/investors/press-releases/detail/340/trevena-reports-first-quarter-2024-results-and-provides-business-update https://www.trevena.com/investors/press-releases/detail/339/trevena-reports-fourth-quarter-2023-results-and-provides-corporate-update https://www.trevena.com/investors/press-releases/detail/338/trevena-announces-the-closing-of4-million-concurrent-private-placement-and-warrant-exercise https://www.trevena.com/investors/press-releases/detail/337/trevena-inc-announces-4-million-concurrent-private-placementand-warrant-exercise https://www.trevena.com/investors/press-releases/detail/336/trevena-announces-trv045-presentation-at-the-american-college-of-neuropsychopharmacology-62nd-annual-meeting https://www.trevena.com/investors/press-releases/detail/335/trevena-awarded-olinvyk-agreement-with-premier-inc https://www.trevena.com/investors/press-releases/detail/334/trevena-announces-acceptance-of-abstract-examining-the-use-of-olinvyk-in-patients-with-acute-burn-injuries https://www.trevena.com/investors/press-releases/detail/333/trevena-reports-third-quarter-2023-results-and-provides-business-update https://www.trevena.com/investors/press-releases/detail/332/trevena-to-release-third-quarter-2023-financial-results-on-november-14-2023 https://www.trevena.com/investors/press-releases/detail/331/trevena-reports-favorable-trv045-topline-safety-and-tolerability-data-from-proof-of-concept-studies https://www.trevena.com/investors/press-releases/detail/330/trevena-announces-completion-of-initial-analysis-of-olinvyk-continuous-respiratory-monitoring-data-from-volition-study-and-presentation-at-american-society-of-anesthesiologists-conference https://www.trevena.com/investors/press-releases/detail/329/trevena-announces-receipt-of-15-million-non-dilutive-tranche-and-provides-general-business-update https://www.trevena.com/investors/press-releases/detail/328/trevena-announces-preliminary-trv045-data-from-two-proof-of-concept-studies-evaluating-s1pr-mechanism-of-action-and-cns-target-engagement https://www.trevena.com/investors/press-releases/detail/327/trevena-reports-second-quarter-2023-results-and-provides-business-update https://www.trevena.com/investors/press-releases/detail/326/trevena-inc-appoints-mark-corrigan-m-d-to-board-of-directors https://www.trevena.com/investors/press-releases/detail/325/trevena-announces-new-topline-olinvyk-data-highlighting-reduced-cost-per-admission-from-artemis-real-world-outcomes-study https://www.trevena.com/investors/press-releases/detail/324/trevena-announces-receipt-of-milestone-payment-from-partner-in-china-jiangsu-nhwa-pharmaceutical https://www.trevena.com/investors/press-releases/detail/323/trevena-regains-compliance-with-nasdaq-listing-and-reaffirms-expected-near-term-milestones https://www.trevena.com/investors/press-releases/detail/322/trevena-reports-first-quarter-2023-results-and-provides-business-update https://www.trevena.com/investors/press-releases/detail/321/trevena-to-release-first-quarter-2023-financial-results-on-may-15-2023 https://www.trevena.com/investors/press-releases/detail/320/trevena-announces-approval-of-olinvyk-in-china https://www.trevena.com/investors/press-releases/detail/319/trevena-to-participate-in-three-upcoming-conferences https://www.trevena.com/investors/press-releases/detail/318/trevena-announces-initial-topline-olinvyk-data-from-~200-patient-real-world-clinical-outcomes-study https://www.trevena.com/investors/press-releases/detail/317/trevena-reports-fourth-quarter-2022-results-and-provides-business-update https://www.trevena.com/investors/press-releases/detail/316/trevena-to-release-fourth-quarter-and-full-year-2022-financial-results-on-march-30-2023 https://www.trevena.com/investors/press-releases/detail/315/trevena-initiates-targeted-proof-of-concept-study-to-evaluate-trv045-as-a-potential-treatment-for-epilepsy-and-other-cns-disorders https://www.trevena.com/investors/press-releases/detail/314/trevena-announces-publication-of-olinvyk-respiratory-physiology-study-in-anesthesiology https://www.trevena.com/investors/press-releases/detail/313/trevena-enrolls-first-subject-in-trv045-proof-of-concept-trial-evaluating-s1pr-mechanism-of-action-and-target-engagement https://www.trevena.com/investors/press-releases/detail/311/trevena-regains-compliance-with-nasdaq-listing-requirements https://www.trevena.com/investors/press-releases/detail/310/trevena-inc-announces-8-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules https://www.trevena.com/investors/press-releases/detail/309/trevena-announces-reverse-stock-split https://www.trevena.com/investors/press-releases/detail/308/trevena-announces-completion-of-phase-1-study-for-trv045-novel-s1p-receptor-modulator https://www.trevena.com/investors/press-releases/detail/307/trevena-reports-third-quarter-2022-results-and-provides-business-update https://www.trevena.com/investors/press-releases/detail/306/trevena-to-release-third-quarter-2022-financial-results-on-november-9-2022 https://www.trevena.com/investors/press-releases/detail/305/trevena-announces-olinvyk-poster-presentation-at-the-anesthesiology-2022-annual-meeting https://www.trevena.com/investors/press-releases/detail/304/trevena-to-participate-at-the-h-c-wainwright-annual-global-investment-conference https://www.trevena.com/investors/press-releases/detail/303/trevena-reports-second-quarter-2022-results-and-provides-business-update https://www.trevena.com/investors/press-releases/detail/302/trevena-to-release-second-quarter-2022-financial-results-on-august-11-2022 https://www.trevena.com/investors/press-releases/detail/301/trevena-inc-announces-closing-of-registered-direct-offering-of-preferred-stock https://www.trevena.com/investors/press-releases/detail/300/trevena-inc-announces-registered-direct-offering-of-preferred-stock https://www.trevena.com/investors/press-releases/detail/299/trevena-announces-positive-topline-olinvyk-cognitive-function-data-and-provides-general-business-update https://www.trevena.com/investors/press-releases/detail/298/trevena-announces-the-publication-of-an-expert-review-on-the-clinical-profile-of-olinvyk-in-post-operative-care https://www.trevena.com/investors/press-releases/detail/297/trevena-to-participate-at-the-jmp-securities-life-sciences-conference https://www.trevena.com/investors/press-releases/detail/296/trevena-to-present-at-the-h-c-wainwright-global-investment-conference https://www.trevena.com/investors/press-releases/detail/295/trevena-reports-first-quarter-2022-results-and-provides-business-update https://www.trevena.com/investors/press-releases/detail/294/trevena-to-release-first-quarter-2022-financial-results-on-may-11-2022 https://www.trevena.com/investors/press-releases/detail/293/trevena-announces-results-from-respiratory-physiology-study-of-head-to-head-comparison-of-olinvyk-and-iv-morphine-in-elderlyoverweight-subjects https://www.trevena.com/investors/press-releases/detail/292/trevena-announces-receipt-of-first-15-million-tranche-in-connection-with-its-40-million-ex-us-royalty-based-financing-with-r-bridge-healthcare-fund https://www.trevena.com/investors/press-releases/detail/291/olinvyk-data-selected-as-presidents-choice-abstract-at-annual-regional-anesthesiology-and-acute-pain-medicine-meeting-and-featured-at-american-burn-association-annual-meeting https://www.trevena.com/investors/press-releases/detail/290/trevena-receives-up-to-40m-in-olinvyk-ex-us-royalty-based-financing-from-r-bridge-healthcare-fund-an-affiliate-of-cbc-group https://www.trevena.com/investors/press-releases/detail/289/trevena-reports-fourth-quarter-and-full-year-2021-results https://www.trevena.com/investors/press-releases/detail/288/trevena-to-release-fourth-quarter-and-full-year-2021-financial-results-on-march-31-2022 https://www.trevena.com/investors/press-releases/detail/287/trevena-to-present-at-the-2022-bio-ceo-investor-conference https://www.trevena.com/investors/press-releases/detail/286/trevena-announces-submission-of-new-drug-application-in-china-for-olinvyk-by-its-partner-jiangsu-nhwa-pharmaceutical https://www.trevena.com/investors/press-releases/detail/285/trevena-to-participate-in-the-upcoming-january-conferences https://www.trevena.com/investors/press-releases/detail/284/trevena-announces-advancement-of-trv045-into-clinical-development-for-diabetic-neuropathic-pain https://www.trevena.com/investors/press-releases/detail/283/trevena-reports-third-quarter-2021-results https://www.trevena.com/investors/press-releases/detail/282/trevena-adds-seasoned-biopharma-commercial-executive-to-senior-leadership-team https://www.trevena.com/investors/press-releases/detail/281/trevena-to-release-third-quarter-2021financial-results-on-november-15th-2021 https://www.trevena.com/investors/press-releases/detail/280/trevena-announces-two-olinvyk-presentations-at-anesthesiology-2021 https://www.trevena.com/investors/press-releases/detail/279/trevena-announces-results-of-trv027-proof-of-concept-study-in-covid-19-patients https://www.trevena.com/investors/press-releases/detail/278/trevena-to-present-at-the-oppenheimer-2021-fall-healthcare-life-sciences-medtech-summit https://www.trevena.com/investors/press-releases/detail/277/trevena-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference https://www.trevena.com/investors/press-releases/detail/276/trevena-announces-two-olinvyk-abstracts-highlighting-safety-data-accepted-at-anesthesiology-2021 https://www.trevena.com/investors/press-releases/detail/275/trevena-announces-wake-forest-baptist-health-joining-olinvyk-clinical-outcomes-study https://www.trevena.com/investors/press-releases/detail/274/trevena-reports-second-quarter-2021-results https://www.trevena.com/investors/press-releases/detail/273/trevena-announces-publication-highlighting-risk-benefit-analysis-of-olinvyk-in-pain-and-therapy https://www.trevena.com/investors/press-releases/detail/272/trevena-to-release-second-quarter-2021-financial-results-on-august-12th-2021 https://www.trevena.com/investors/press-releases/detail/271/trevena-announces-first-patient-enrolled-in-nih-funded-activ-4-host-tissue-trial-of-trv027-for-covid-19 https://www.trevena.com/investors/press-releases/detail/270/trevena-announces-two-leading-independent-proxy-advisory-firms-recommend-shareholders-vote-for-all-proposals-ahead-of-special-meeting-of-stockholders https://www.trevena.com/investors/press-releases/detail/269/trevena-announces-publication-of-olinvyk-health-economic-model-in-journal-of-comparative-effectiveness-research https://www.trevena.com/investors/press-releases/detail/268/trevena-announces-first-patient-enrolled-in-olinvyk-phase-3-trial-in-china-in-partnership-with-jiangsu-nhwa-pharmaceutical https://www.trevena.com/investors/press-releases/detail/267/trevena-announces-initiation-of-olinvyk-respiratory-physiology-study-including-elderly-obese-subjects https://www.trevena.com/investors/press-releases/detail/266/trevena-added-to-russell-2000-russell-3000-and-russell-microcap-indexes https://www.trevena.com/investors/press-releases/detail/265/trevena-announces-nih-has-resumed-recruiting-patients-in-proof-of-concept-study-for-trv734-in-opioid-use-disorder https://www.trevena.com/investors/press-releases/detail/264/trevena-to-present-at-the-jmp-securities-life-sciences-conference https://www.trevena.com/investors/press-releases/detail/263/trevena-announces-presentations-of-olinvyk-health-economic-models-at-ispor-2021 https://www.trevena.com/investors/press-releases/detail/262/trevena-announces-presentation-of-olinvyk-respiratory-safety-data-in-high-risk-patients-at-the-46th-annual-asra-meeting https://www.trevena.com/investors/press-releases/detail/261/trevena-announces-trv027-selected-by-nih-funded-activ-initiative-for-covid-19-trial https://www.trevena.com/investors/press-releases/detail/260/trevena-reports-first-quarter-2021-results https://www.trevena.com/investors/press-releases/detail/259/trevena-to-release-first-quarter-2021-financial-results-on-may-6-2021 https://www.trevena.com/investors/press-releases/detail/258/trevena-inc-to-participate-at-the-sachs-associates-4th-annual-neuroscience-innovation-forum https://www.trevena.com/investors/press-releases/detail/257/trevena-announces-trv027-selected-for-study-in-global-remap-cap-trial-in-covid-19-patients https://www.trevena.com/investors/press-releases/detail/256/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting https://www.trevena.com/investors/press-releases/detail/255/trevena-inc-appoints-marvin-h-johnson-jr-to-board-of-directors https://www.trevena.com/investors/press-releases/detail/254/trevena-inc-reports-fourth-quarter-and-full-year-2020-results https://www.trevena.com/investors/press-releases/detail/253/trevena-to-release-fourth-quarter-and-full-year-2020-financial-results-on-march-9-2021 https://www.trevena.com/investors/press-releases/detail/252/trevena-inc-to-participate-in-march-virtual-investor-conferences https://www.trevena.com/investors/press-releases/detail/251/trevena-inc-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference https://www.trevena.com/investors/press-releases/detail/250/trevena-inc-announces-publication-highlighting-olinvyk-respiratory-safety-data-in-high-risk-patients-in-pain-therapy https://www.trevena.com/investors/press-releases/detail/249/trevena-inc-to-participate-in-two-upcoming-virtual-investor-conferences https://www.trevena.com/investors/press-releases/detail/248/trevena-inc-provides-update-on-commercial-launch-activities-for-olinvyk-and-announces-anticipated-pipeline-catalysts https://www.trevena.com/investors/press-releases/detail/247/trevena-inc-announces-presentations-highlighting-novel-s1p1-receptor-modulator-at-the-american-college-of-neuropsychopharmacology-59th-annual-meeting https://www.trevena.com/investors/press-releases/detail/246/trevena-inc-announces-publication-highlighting-gi-tolerability-profile-of-olinvyk-oliceridine-injection-in-pain-and-therapy https://www.trevena.com/investors/press-releases/detail/245/trevena-inc-to-participate-in-the-following-november-virtual-investor-conferences https://www.trevena.com/investors/press-releases/detail/244/trevena-inc-announces-dea-scheduling-of-olinvyk-oliceridine-injection https://www.trevena.com/investors/press-releases/detail/243/trevena-inc-announces-three-olinvyk-presentations-at-the-virtual-american-society-of-anesthesiologists-2020-annual-meeting https://www.trevena.com/investors/press-releases/detail/242/trevena-inc-announces-presentations-at-the-virtual-2020-american-college-of-clinical-pharmacology-annual-meeting https://www.trevena.com/investors/press-releases/detail/241/trevena-inc-to-present-at-septembervirtual-investor-conferences https://www.trevena.com/investors/press-releases/detail/240/trevena-announces-publications-of-olinvyk-respiratory-safety-analyses-vs-iv-morphine https://www.trevena.com/investors/press-releases/detail/239/trevena-announces-initiation-of-trv027-study-in-covid-19-patients-in-collaboration-with-imperial-college-london https://www.trevena.com/investors/press-releases/detail/238/trevena-announces-receipt-of-milestone-payment-under-partnership-in-china-with-jiangsu-nhwa-pharmaceutical-co https://www.trevena.com/investors/press-releases/detail/237/trevena-to-present-at-the-virtual-jmp-securities-cns-forum https://www.trevena.com/investors/press-releases/detail/236/trevena-announces-pricing-of-50-million-public-offering-of-common-stock https://www.trevena.com/investors/press-releases/detail/235/trevena-announces-proposed-public-offering-of-common-stock https://www.trevena.com/investors/press-releases/detail/234/trevena-announces-fda-approval-of-olinvyk-oliceridine-injection https://www.trevena.com/investors/press-releases/detail/233/trevena-announces-advancement-of-oliceridine-clinical-development-in-china-by-jiangsu-nhwa-pharmaceutical-co https://www.trevena.com/investors/press-releases/detail/232/trevena-announces-collaboration-with-imperial-college-london-to-evaluate-trv027-in-covid-19-patients https://www.trevena.com/investors/press-releases/detail/231/trevena-reports-first-quarter-2020-results https://www.trevena.com/investors/press-releases/detail/230/trevena-to-release-first-quarter-2020-financial-results-on-may-7-2020 https://www.trevena.com/investors/press-releases/detail/229/trevena-announces-publication-of-comprehensive-review-of-oliceridine-data https://www.trevena.com/investors/press-releases/detail/228/trevena-reports-fourth-quarter-and-full-year-2019-results https://www.trevena.com/investors/press-releases/detail/227/trevena-to-report-fourth-quarter-and-full-year-2019-results-on-march-12-2020 https://www.trevena.com/investors/press-releases/detail/226/trevena-announces-fda-has-set-pdufa-date-of-august-7-2020-for-oliceridine https://www.trevena.com/investors/press-releases/detail/225/trevena-appoints-scott-applebaum-as-chief-legal-and-compliance-officer-and-svp-of-regulatory-affairs https://www.trevena.com/investors/press-releases/detail/224/trevena-resubmits-new-drug-application-for-oliceridine https://www.trevena.com/investors/press-releases/detail/223/trevena-to-present-at-the-2020-bio-ceo-investor-conference https://www.trevena.com/investors/press-releases/detail/222/trevena-announces-initiation-of-proof-of-concept-study-for-trv734-for-potential-treatment-of-opioid-use-disorder https://www.trevena.com/investors/press-releases/detail/221/trevena-presents-phase-1-data-on-trv250-for-acute-migraine-at-american-college-of-neuropsychopharmacology-2019-annual-meeting https://www.trevena.com/investors/press-releases/detail/220/trevena-announces-publication-of-results-from-special-population-studies-for-oliceridine https://www.trevena.com/investors/press-releases/detail/219/trevena-announces-publication-of-results-from-phase-3-real-world-safety-study-for-oliceridine-in-the-journal-of-pain-research https://www.trevena.com/investors/press-releases/detail/218/trevena-to-present-at-the-stifel-2019-healthcare-conference https://www.trevena.com/investors/press-releases/detail/217/trevena-reports-third-quarter-2019-results-and-topline-data-from-multi-dose-healthy-volunteer-qt-study https://www.trevena.com/investors/press-releases/detail/216/trevena-announces-presentations-at-the-american-society-of-anesthesiologists-2019-annual-meeting https://www.trevena.com/investors/press-releases/detail/215/trevena-to-present-at-the-2019-cantor-global-healthcare-conference https://www.trevena.com/investors/press-releases/detail/214/trevena-to-participate-in-upcoming-conferences-in-september-2019 https://www.trevena.com/investors/press-releases/detail/213/trevena-advances-nda-resubmission-activities-for-oliceridine https://www.trevena.com/investors/press-releases/detail/212/trevena-reports-second-quarter-2019-results https://www.trevena.com/investors/press-releases/detail/211/trevena-to-report-second-quarter-2019-results-on-august-7-2019 https://www.trevena.com/investors/press-releases/detail/210/trevena-appoints-barry-shin-as-chief-financial-officer https://www.trevena.com/investors/press-releases/detail/209/trevena-announces-publication-of-apollo-2-results-in-pain-practice https://www.trevena.com/investors/press-releases/detail/5/trevena-announces-initiation-of-healthy-volunteer-study-for-oliceridine https://www.trevena.com/investors/press-releases/detail/166/trevena-to-participate-in-upcoming-conferences-in-june-2019 https://www.trevena.com/investors/press-releases/detail/165/trevena-reports-first-quarter-2019-results https://www.trevena.com/investors/press-releases/detail/164/trevena-reports-fourth-quarter-and-full-year-2018-results https://www.trevena.com/investors/press-releases/detail/208/trevena-announces-publication-of-apollo-1-results-in-the-journal-of-pain-research-highlighting-oliceridines-potential-for-management-of-moderate-to-severe-acute-pain https://www.trevena.com/investors/press-releases/detail/163/trevena-to-report-fourth-quarter-and-full-year-2018-results-on-march-13-2019 https://www.trevena.com/investors/press-releases/detail/162/trevena-to-present-at-the-21st-annual-bio-ceo-investor-conference https://www.trevena.com/investors/press-releases/detail/161/trevena-announces-10-million-registered-direct-offering-of-common-stock https://www.trevena.com/investors/press-releases/detail/160/trevena-announces-receipt-of-type-a-meeting-minutes-and-provides-regulatory-update-for-oliceridine https://www.trevena.com/investors/press-releases/detail/159/national-institute-on-drug-abuse-presents-data-on-trevenas-trv734-at-the-57th-annual-meeting-of-the-american-college-of-neuropsychopharmacology https://www.trevena.com/investors/press-releases/detail/158/trevena-promotes-robert-t-yoder-to-senior-vice-president-and-chief-business-officer https://www.trevena.com/investors/press-releases/detail/157/trevena-reports-third-quarter-2018-financial-results-and-announces-workforce-restructuring https://www.trevena.com/investors/press-releases/detail/156/trevena-receives-complete-response-letter-for-oliceridine-from-fda https://www.trevena.com/investors/press-releases/detail/155/trevena-to-present-phase-3-open-label-safety-study-of-oliceridine-at-the-american-society-of-anesthesiologists-annual-meeting https://www.trevena.com/investors/press-releases/detail/154/trevena-announces-oliceridine-fda-advisory-committee-meeting-outcome https://www.trevena.com/investors/press-releases/detail/153/trevena-stock-trading-halted-fda-advisory-committee-to-review-oliceridine-for-the-treatment-of-moderate-to-severe-acute-pain https://www.trevena.com/investors/press-releases/detail/152/trevena-announces-completion-of-leadership-transition-and-appointment-of-new-director https://www.trevena.com/investors/press-releases/detail/151/trevena-to-present-oliceridine-a-next-generation-iv-opioid-for-the-management-of-moderate-to-severe-acute-pain-at-fda-advisory-committee-meeting-on-october-11-2018 https://www.trevena.com/investors/press-releases/detail/150/trevena-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conference https://www.trevena.com/investors/press-releases/detail/149/trevena-reports-second-quarter-2018-financial-results https://www.trevena.com/investors/press-releases/detail/148/trevena-announces-successful-completion-of-phase-1-study-of-trv250-for-acute-migraine https://www.trevena.com/investors/press-releases/detail/147/trevena-expands-commercial-and-medical-affairs-leadership-teams-with-key-hires https://www.trevena.com/investors/press-releases/detail/146/trevena-to-present-at-the-jefferies-global-healthcare-conference https://www.trevena.com/investors/press-releases/detail/145/trevena-announces-presentations-at-the-american-society-of-colon-and-rectal-surgeons-2018-annual-scientific-meeting https://www.trevena.com/investors/press-releases/detail/144/trevena-appoints-mark-a-demitrack-m-d-as-chief-medical-officer https://www.trevena.com/investors/press-releases/detail/143/trevena-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 https://www.trevena.com/investors/press-releases/detail/142/trevena-reports-first-quarter-2018-financial-results https://www.trevena.com/investors/press-releases/detail/141/trevena-to-present-at-the-deutsche-bank-43rd-annual-healthcare-conference https://www.trevena.com/investors/press-releases/detail/140/trevena-inc-and-jiangsu-nhwa-pharmaceutical-co-ltd-announce-license-agreement-for-oliceridine-in-china https://www.trevena.com/investors/press-releases/detail/139/trevena-and-pharmbio-korea-announce-license-and-commercialization-agreement-for-oliceridine-in-south-korea https://www.trevena.com/investors/press-releases/detail/138/trevena-to-report-first-quarter-2018-financial-results-on-may-3-2018 https://www.trevena.com/investors/press-releases/detail/137/trevena-announces-retirement-of-maxine-gowen-ph-d-effective-october-1-and-planned-promotion-of-carrie-l-bourdow-to-president-and-chief-executive-officer https://www.trevena.com/investors/press-releases/detail/136/trevena-to-present-at-the-needham-company-17th-annual-healthcare-conference https://www.trevena.com/investors/press-releases/detail/135/trevena-to-present-at-the-oppenheimer-company-28th-annual-healthcare-conference https://www.trevena.com/investors/press-releases/detail/134/trevena-to-present-at-the-cowen-and-company-38th-annual-healthcare-conference https://www.trevena.com/investors/press-releases/detail/133/trevena-reports-full-year-2017-earnings https://www.trevena.com/investors/press-releases/detail/132/trevena-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 https://www.trevena.com/investors/press-releases/detail/131/trevena-to-host-conference-call-on-march-7th-to-discuss-full-year-2017-financial-results https://www.trevena.com/investors/press-releases/detail/130/trevena-promotes-carrie-bourdow-to-executive-vice-president-and-chief-operating-officer https://www.trevena.com/investors/press-releases/detail/129/trevena-announces-fda-acceptance-for-review-of-new-drug-application-for-olinvo-oliceridine-injection https://www.trevena.com/investors/press-releases/detail/128/trevena-reports-third-quarter-2017-financial-results-and-announces-new-positive-clinical-trial-data https://www.trevena.com/investors/press-releases/detail/127/trevena-announces-submission-of-new-drug-application-to-u-s-fda-for-olinvo-oliceridine-injection https://www.trevena.com/investors/press-releases/detail/126/trevena-to-report-third-quarter-2017-financial-results-on-november-7-2017 https://www.trevena.com/investors/press-releases/detail/125/trevena-announces-publication-and-presentations-of-olinvo-oliceridine-injection-clinical-data https://www.trevena.com/investors/press-releases/detail/124/trevena-announces-restructuring-to-focus-resources-on-commercial-strategy https://www.trevena.com/investors/press-releases/detail/123/trevena-to-present-at-the-ladenburg-thalmann-3rd-annual-2017-healthcare-conference https://www.trevena.com/investors/press-releases/detail/122/trevena-announces-presentations-during-painweek-2017 https://www.trevena.com/investors/press-releases/detail/121/trevena-to-present-at-the-rodman-renshaw-19th-annual-global-investment-conference https://www.trevena.com/investors/press-releases/detail/120/trevena-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 https://www.trevena.com/investors/press-releases/detail/119/trevena-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 https://www.trevena.com/investors/press-releases/detail/118/trevena-reports-second-quarter-2017-financial-results-and-provides-corporate-update https://www.trevena.com/investors/press-releases/detail/117/trevena-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 https://www.trevena.com/investors/press-releases/detail/116/trevena-to-host-2017-analyst-day-and-announce-results-of-athena-open-label-safety-study-of-olinvo https://www.trevena.com/investors/press-releases/detail/115/trevena-to-host-analyst-day-on-july-20-2017 https://www.trevena.com/investors/press-releases/detail/114/trevena-attends-national-institutes-of-health-meeting-to-discuss-development-of-novel-improved-pain-medications https://www.trevena.com/investors/press-releases/detail/113/trevena-to-present-at-investor-conferences-in-june https://www.trevena.com/investors/press-releases/detail/112/trevena-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 https://www.trevena.com/investors/press-releases/detail/111/trevena-announces-presentations-during-the-36th-annual-scientific-meeting-of-the-american-pain-society https://www.trevena.com/investors/press-releases/detail/110/trevena-reports-first-quarter-2017-financial-results-and-provides-corporate-update https://www.trevena.com/investors/press-releases/detail/109/trevena-to-present-at-the-deutsche-bank-securities-42nd-annual-healthcare-conference https://www.trevena.com/investors/press-releases/detail/108/trevena-announces-presentations-at-the-42nd-annual-regional-anesthesiology-and-acute-pain-medicine-meeting https://www.trevena.com/investors/press-releases/detail/107/trevena-to-present-at-needham-companys-16th-annual-healthcare-conference https://www.trevena.com/investors/press-releases/detail/106/trevena-to-present-at-the-oppenheimer-27th-annual-healthcare-conference https://www.trevena.com/investors/press-releases/detail/105/trevena-to-present-at-the-2017-barclays-global-healthcare-conference https://www.trevena.com/investors/press-releases/detail/104/trevena-reports-full-year-2016-earnings https://www.trevena.com/investors/press-releases/detail/103/trevena-to-host-conference-call-on-march-8th-to-discuss-full-year-2016-financial-results https://www.trevena.com/investors/press-releases/detail/102/trevena-announces-positive-top-line-results-from-two-phase-3-pivotal-efficacy-studies-of-intravenous-oliceridine-in-moderate-to-severe-acute-pain https://www.trevena.com/investors/press-releases/detail/101/trevena-completes-enrollment-of-phase-3-apollo-pivotal-efficacy-trials-of-oliceridine-for-moderate-to-severe-acute-pain https://www.trevena.com/investors/press-releases/detail/100/trevena-reports-third-quarter-2016-financial-results-and-provides-corporate-update https://www.trevena.com/investors/press-releases/detail/99/trevena-announces-highlights-from-recent-presentations https://www.trevena.com/investors/press-releases/detail/98/trevena-to-webcast-thought-leader-symposium-on-acute-pain-management-and-present-at-the-2016-annual-meeting-of-the-american-society-of-anesthesiologists https://www.trevena.com/investors/press-releases/detail/97/trevena-to-present-at-the-2016-wedbush-pacgrow-healthcare-conference https://www.trevena.com/investors/press-releases/detail/96/company-profile-for-trevena-inc https://www.trevena.com/investors/press-releases/detail/95/trevena-reports-second-quarter-2016-financial-results-and-provides-corporate-update https://www.trevena.com/investors/press-releases/detail/94/trevena-to-present-at-the-jmp-life-sciences-conference https://www.trevena.com/investors/press-releases/detail/93/trevena-inc-announces-first-patients-enrolled-in-the-apollo-1-and-apollo-2-phase-3-pivotal-efficacy-studies-of-oliceridine-in-acute-pain https://www.trevena.com/investors/press-releases/detail/92/trevena-to-present-at-the-jefferies-2016-healthcare-conference https://www.trevena.com/investors/press-releases/detail/91/trevena-reports-trv027-did-not-achieve-primary-or-secondary-endpoints-in-blast-ahf-phase-2b-trial-in-acute-heart-failure https://www.trevena.com/investors/press-releases/detail/90/trevena-announces-presentations-at-the-35th-annual-scientific-meeting-of-the-american-pain-society https://www.trevena.com/investors/press-releases/detail/89/trevena-reports-first-quarter-2016-financial-results-and-provides-corporate-update https://www.trevena.com/investors/press-releases/detail/88/trevena-announces-successful-end-of-phase-2-meeting-with-fda-and-outlines-phase-3-program-for-oliceridine https://www.trevena.com/investors/press-releases/detail/87/trevena-announces-blast-ahf-phase-2b-trial-results-will-be-presented-at-the-heart-failure-2016-conference https://www.trevena.com/investors/press-releases/detail/86/trevena-to-present-at-the-needham-company-15th-annual-healthcare-conference https://www.trevena.com/investors/press-releases/detail/85/trevena-announces-presentations-at-the-41st-annual-regional-anesthesiology-and-acute-pain-medicine-meeting https://www.trevena.com/investors/press-releases/detail/84/trevena-reports-full-year-2015-financial-results https://www.trevena.com/investors/press-releases/detail/83/trevena-to-present-at-three-upcoming-investor-events-in-march https://www.trevena.com/investors/press-releases/detail/82/trevena-to-host-conference-call-on-march-9th-to-discuss-full-year-2015-financial-results https://www.trevena.com/investors/press-releases/detail/81/trevena-inc-receives-fda-breakthrough-therapy-designation-for-oliceridine-for-the-management-of-moderate-to-severe-acute-pain https://www.trevena.com/investors/press-releases/detail/80/trevena-to-present-at-the-2016-rbc-capital-markets-global-healthcare-conference https://www.trevena.com/investors/press-releases/detail/79/trevena-to-present-at-the-18th-annual-bio-ceo-investor-conference https://www.trevena.com/investors/press-releases/detail/78/trevena-inc-announces-initiation-of-oliceridine-phase-3-clinical-program-with-multi-procedure-safety-and-tolerability-study https://www.trevena.com/investors/press-releases/detail/77/trevena-inc-added-to-nasdaq-biotechnology-index-nbi https://www.trevena.com/investors/press-releases/detail/76/trevena-announces-fda-grant-of-fast-track-designation-to-oliceridine-trv130-for-the-management-of-moderate-to-severe-acute-pain https://www.trevena.com/investors/press-releases/detail/75/trevena-granted-key-composition-of-matter-and-use-patent-for-trv027-in-europe https://www.trevena.com/investors/press-releases/detail/74/trevena-to-present-at-the-oppenheimer-26th-annual-healthcare-conference https://www.trevena.com/investors/press-releases/detail/73/trevena-ceo-to-present-at-the-jefferies-2015-global-healthcare-conference https://www.trevena.com/investors/press-releases/detail/72/trevena-reports-third-quarter-2015-financial-results-and-provides-corporate-update https://www.trevena.com/investors/press-releases/detail/71/trevena-hosts-investor-and-analyst-day https://www.trevena.com/investors/press-releases/detail/70/trevena-to-host-analyst-and-investor-day-on-october-28-2015 https://www.trevena.com/investors/press-releases/detail/69/trevena-announces-publication-of-trv130-phase-2-bunionectomy-data-in-the-journal-pain https://www.trevena.com/investors/press-releases/detail/68/trevena-inc-announces-closing-of-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares https://www.trevena.com/investors/press-releases/detail/67/trevena-inc-announces-pricing-of-underwritten-offering-of-common-stock https://www.trevena.com/investors/press-releases/detail/66/trevena-inc-announces-proposed-underwritten-offering-of-common-stock https://www.trevena.com/investors/press-releases/detail/65/trevena-announces-presentations-at-painweek-2015 https://www.trevena.com/investors/press-releases/detail/64/trevena-announces-positive-results-from-phase-2b-study-of-trv130-in-acute-postoperative-pain https://www.trevena.com/investors/press-releases/detail/63/trevena-reports-second-quarter-2015-financial-results-and-provides-a-corporate-update https://www.trevena.com/investors/press-releases/detail/62/trevena-ceo-to-present-at-the-2015-wedbush-pacgrow-healthcare-conference https://www.trevena.com/investors/press-releases/detail/61/trevena-appoints-yacoub-habib-as-senior-vice-president-business-development-and-corporate-planning https://www.trevena.com/investors/press-releases/detail/60/trevena-added-to-russell-3000-russell-2000-and-russell-global-indexes https://www.trevena.com/investors/press-releases/detail/59/trevena-announces-poster-presentation-of-data-for-delta-receptor-compound-trv250-at-american-headache-society-57th-annual-scientific-meeting https://www.trevena.com/investors/press-releases/detail/58/trevena-ceo-to-present-at-the-2015-jmp-securities-life-sciences-conference https://www.trevena.com/investors/press-releases/detail/57/trevena-granted-key-u-s-composition-of-matter-patent-for-trv734 https://www.trevena.com/investors/press-releases/detail/56/trevena-ceo-to-present-at-the-jefferies-2015-global-healthcare-conference https://www.trevena.com/investors/press-releases/detail/55/trevena-announces-presentation-of-preclinical-data-for-delta-receptor-compound-trv250-at-international-headache-congress https://www.trevena.com/investors/press-releases/detail/54/trevena-reports-first-quarter-2015-financial-results-and-provides-a-corporate-update https://www.trevena.com/investors/press-releases/detail/53/trevena-appoints-carrie-bourdow-as-chief-commercial-officer https://www.trevena.com/investors/press-releases/detail/52/trevena-ceo-to-present-at-the-14th-annual-needham-healthcare-conference https://www.trevena.com/investors/press-releases/detail/47/trevena-cmo-to-present-at-the-biocentury-22nd-annual-future-leaders-in-the-biotech-industry-conference https://www.trevena.com/investors/press-releases/detail/51/trevena-reports-full-year-2014-financial-results https://www.trevena.com/investors/press-releases/detail/50/trevena-to-host-conference-call-on-march-18th-to-discuss-full-year-2014-financial-results https://www.trevena.com/investors/press-releases/detail/48/trevena-completes-interim-analysis-and-announces-plans-for-ongoing-phase-2b-blast-ahf-trial-of-trv027-in-acute-heart-failure https://www.trevena.com/investors/press-releases/detail/49/trevena-ceo-to-present-at-the-barclays-global-healthcare-conference https://www.trevena.com/investors/press-releases/detail/45/trevena-ceo-to-present-at-the-cowen-and-company-35th-annual-health-care-conference https://www.trevena.com/investors/press-releases/detail/43/trevena-announces-positive-results-from-phase-1-multiple-ascending-dose-study-of-trv734-for-moderate-to-severe-acute-and-chronic-pain https://www.trevena.com/investors/press-releases/detail/44/trevena-ceo-to-present-at-the-17th-annual-bio-ceo-investor-conference https://www.trevena.com/investors/press-releases/detail/46/trv027-phase-2b-blast-ahf-trial-design-published-in-journal-of-the-american-college-of-cardiology-heart-failure https://www.trevena.com/investors/press-releases/detail/42/trevena-initiates-second-phase-2b-study-of-trv130-for-acute-postoperative-pain https://www.trevena.com/investors/press-releases/detail/40/trevena-appoints-anne-m-phillips-to-the-board-of-directors https://www.trevena.com/investors/press-releases/detail/38/trevena-announces-closing-of-public-offering-and-partial-exercise-of-underwriters-option-to-purchase-additional-shares https://www.trevena.com/investors/press-releases/detail/41/trevena-announces-pricing-of-public-offering https://www.trevena.com/investors/press-releases/detail/39/trevena-announces-commencement-of-public-offering https://www.trevena.com/investors/press-releases/detail/36/trevena-announces-positive-top-line-results-from-phase-2ab-study-of-trv130-in-acute-postoperative-pain https://www.trevena.com/investors/press-releases/detail/37/trevena-reports-third-quarter-2014-financial-results-and-provides-a-corporate-update https://www.trevena.com/investors/press-releases/detail/35/trevena-announces-early-completion-of-enrollment-of-phase-2ab-study-of-trv130-in-postoperative-pain https://www.trevena.com/investors/press-releases/detail/34/trevena-enters-into-35-million-tranched-term-loan-credit-facility https://www.trevena.com/investors/press-releases/detail/33/trevena-appoints-adam-m-koppel-to-the-board-of-directors https://www.trevena.com/investors/press-releases/detail/32/trevena-granted-key-u-s-composition-of-matter-patent-for-trv130 https://www.trevena.com/investors/press-releases/detail/27/trevena-reports-second-quarter-2014-financial-results https://www.trevena.com/investors/press-releases/detail/30/trevena-ceo-to-present-at-the-canaccord-genuity-34th-annual-growth-conference https://www.trevena.com/investors/press-releases/detail/28/trevena-initiates-phase-1-multiple-ascending-dose-study-of-trv734-for-acute-and-chronic-pain https://www.trevena.com/investors/press-releases/detail/29/trevena-to-host-conference-call-to-discuss-second-quarter-2014-results-on-august-12 https://www.trevena.com/investors/press-releases/detail/31/trevena-granted-key-u-s-method-of-use-patent-for-trv027 https://www.trevena.com/investors/press-releases/detail/26/trevena-appoints-julie-h-mchugh-and-barbara-yanni-to-the-board-of-directors https://www.trevena.com/investors/press-releases/detail/24/results-of-phase-1b-clinical-trial-comparing-trevenas-trv130-to-morphine-published-in-the-journal-pain https://www.trevena.com/investors/press-releases/detail/23/trevena-announces-positive-phase-1-results-for-trv734-for-acute-and-chronic-pain https://www.trevena.com/investors/press-releases/detail/25/trevena-ceo-to-present-at-the-9th-annual-jmp-securities-healthcare-conference https://www.trevena.com/investors/press-releases/detail/22/trevena-ceo-to-present-at-the-jefferies-2014-global-healthcare-conference https://www.trevena.com/investors/press-releases/detail/16/trevena-highlights-phase-2b-blast-ahf-trial-for-trv027-at-the-european-society-of-cardiology-heart-failure-2014-meeting https://www.trevena.com/investors/press-releases/detail/18/trevena-appoints-john-m-limongelli-as-general-counsel https://www.trevena.com/investors/press-releases/detail/19/trevena-reports-first-quarter-2014-financial-results https://www.trevena.com/investors/press-releases/detail/21/trevena-to-host-conference-call-on-may-9th-to-discuss-first-quarter-2014-financial-results-and-recent-highlights https://www.trevena.com/investors/press-releases/detail/17/trevena-presents-results-from-phase-1b-trial-of-injectable-analgesic-trv130-at-american-society-of-pain-annual-meeting https://www.trevena.com/investors/press-releases/detail/20/trevena-initiates-phase-2-study-of-trv130-in-acute-postoperative-pain https://www.trevena.com/investors/press-releases/detail/15/trevena-ceo-to-present-at-the-13th-annual-needham-healthcare-conference https://www.trevena.com/investors/press-releases/detail/14/trevena-appoints-robert-prachar-as-senior-vice-president-commercial-and-corporate-strategy https://www.trevena.com/investors/press-releases/detail/11/trevena-reports-full-year-2013-financial-results https://www.trevena.com/investors/press-releases/detail/13/trevena-to-host-conference-call-on-march-20th-to-discuss-full-year-2013-financial-results-and-recent-highlights https://www.trevena.com/investors/press-releases/detail/12/trevena-announces-partial-exercise-of-underwriters-overallotment-option https://www.trevena.com/investors/press-releases/detail/10/trevena-ceo-to-present-at-the-barclays-global-healthcare-conference https://www.trevena.com/investors/press-releases/detail/9/trevena-announces-closing-of-initial-public-offering https://www.trevena.com/investors/press-releases/detail/8/trevena-initiates-clinical-development-of-trv734-a-novel-biased-ligand-for-moderate-to-severe-pain https://www.trevena.com/investors/press-releases/detail/7/trevena-to-present-at-the-16th-annual-bio-ceo-investor-conference https://www.trevena.com/investors/press-releases/detail/207/trevena-announces-pricing-of-initial-public-offering-of-9250000-shares-of-common-stock https://www.trevena.com/investors/press-releases/detail/6/trevena-announces-pricing-of-initial-public-offering https://www.trevena.com/investors/press-releases/detail/206/trevena-announces-dosing-of-first-patient-in-phase-2b-blast-ahf-trial-of-trv027-for-acute-heart-failure https://www.trevena.com/investors/press-releases/detail/205/trevena-appoints-francois-nader-md-to-its-board-of-directors https://www.trevena.com/investors/press-releases/detail/204/first-clinical-experience-of-trevenas-lead-cns-biased-ligand-trv130-published-in-journal-of-clinical-pharmacology https://www.trevena.com/investors/press-releases/detail/203/trevena-files-registration-statement-for-proposed-initial-public-offering https://www.trevena.com/investors/press-releases/detail/202/trevena-appoints-roberto-cuca-as-senior-vice-president-chief-financial-officer https://www.trevena.com/investors/press-releases/detail/201/mechanism-for-cardiac-effects-of-trevena-angiotensin-receptor-biased-ligands-examined-in-published-study https://www.trevena.com/investors/press-releases/detail/200/trevena-granted-key-composition-of-matter-patent-for-trv027-in-u-s https://www.trevena.com/investors/press-releases/detail/199/journal-of-clinical-pharmacology-publishes-first-clinical-experience-with-trevenas-heart-failure-biased-ligand-trv027 https://www.trevena.com/investors/press-releases/detail/198/trevena-inc-and-forest-laboratories-announce-a-collaborative-agreement-for-development-of-trv027-for-the-treatment-of-acute-heart-failure https://www.trevena.com/investors/press-releases/detail/197/trevena-inc-to-present-at-the-12th-annual-needham-healthcare-conference https://www.trevena.com/investors/press-releases/detail/196/trevena-to-present-first-in-man-study-results-for-mu-opioid-biased-ligand-trv130 https://www.trevena.com/investors/press-releases/detail/195/trevena-to-present-results-of-trv027-phase-2a-study-in-patients-with-advanced-heart-failure https://www.trevena.com/investors/press-releases/detail/194/trevenas-maxine-gowen-named-ceo-of-the-year-by-pa-bio https://www.trevena.com/investors/press-releases/detail/193/trevena-gpcr-platform-yields-a-novel-mu-opioid-biased-ligand-analgesic-with-side-effect-benefits https://www.trevena.com/investors/press-releases/detail/192/trevena-completes-first-in-human-study-of-trv130-an-injectable-mu-opioid-biased-ligand-for-acute-pain https://www.trevena.com/investors/press-releases/detail/191/trevena-presents-phase-1-clinical-data-for-trv027-a--arrestin-biased-at1r-ligand-at-the-2012-heart-failure-society-of-america-meeting https://www.trevena.com/investors/press-releases/detail/190/trevena-angiotensin-receptor-biased-ligand-promotes-cell-survival-during-acute-cardiac-injury https://www.trevena.com/investors/press-releases/detail/189/trevena-acute-heart-failure-drug-trv027-unloads-the-heart-and-maintains-renal-function-when-co-administered-with-furosemide-in-dog-heart-failure-model https://www.trevena.com/investors/press-releases/detail/188/trevena-enters-research-collaboration-with-merck-to-identify-novel-biased-ligand-molecules https://www.trevena.com/investors/press-releases/detail/187/trevena-initiates-clinical-development-of-trv130-a-biased-mu-opioid-ligand-for-severe-post-operative-pain https://www.trevena.com/investors/press-releases/detail/186/trevena-receives-research-funding-for-parkinsons-disease-from-the-michael-j-fox-foundation https://www.trevena.com/investors/press-releases/detail/185/trevena-ceo-to-present-at-the-2011-ubs-global-life-sciences-conference https://www.trevena.com/investors/press-releases/detail/184/cardiorenal-actions-of-trevena-biased-ligand-heart-failure-drug-explained-in-mayo-clinic-publication-and-presentations https://www.trevena.com/investors/press-releases/detail/183/trevena-receives-major-new-award-from-nih-to-develop-delta-opioid-biased-ligand-drug https://www.trevena.com/investors/press-releases/detail/182/trevena-names-arthur-fratamico-chief-business-officer https://www.trevena.com/investors/press-releases/detail/181/trevena-initiates-phase-2-study-of-trv120027-for-acute-heart-failure https://www.trevena.com/investors/press-releases/detail/180/trevena-ceo-to-present-at-the-2011-bio-ceo-and-investor-conference https://www.trevena.com/investors/press-releases/detail/179/trevena-ceo-maxine-gowen-ph-d-named-best-executive-at-annual-stevier-awards-ceremony https://www.trevena.com/investors/press-releases/detail/178/trevena-ceo-to-present-at-the-2010-ubs-global-life-sciences-conference https://www.trevena.com/investors/press-releases/detail/177/trevena-presents-preclinical-data-for-trv120027-a-biased-at1r-ligand-at-the-14th-annual-heart-failure-society-of-america-meeting https://www.trevena.com/investors/press-releases/detail/176/trevena-secures-35-million-in-series-b-funding-to-progress-portfolio-of-gpcr-biased-ligands-and-to-complete-phase-2-study-of-trv120027-for-acute-heart-failure https://www.trevena.com/investors/press-releases/detail/175/trevena-data-showcasing-gpcr-biased-ligands-featured-at-scientific-conferences https://www.trevena.com/investors/press-releases/detail/174/trevena-initiates-clinical-development-of-trv120027-a-first-in-class-biased-ligand https://www.trevena.com/investors/press-releases/detail/173/trevena-names-david-soergel-m-d-vice-president-and-head-clinical-development https://www.trevena.com/investors/press-releases/detail/172/trevena-scientific-co-founder-and-scientific-advisory-board-member-honored-with-2009-bbva-foundation-frontiers-of-knowledge-award https://www.trevena.com/investors/press-releases/detail/171/trevena-awarded-7-65-million-nih-grant-to-accelerate-identification-and-selection-of-biased-gpcr-ligands https://www.trevena.com/investors/press-releases/detail/170/trevena-inc-announces-scientific-advisory-board https://www.trevena.com/investors/press-releases/detail/169/trevena-inc-named-by-businessweek-as-one-of-the-most-successful-u-s-startups-2008 https://www.trevena.com/investors/press-releases/detail/168/trevena-inc-founder-honored-with-national-medal-of-science https://www.trevena.com/investors/press-releases/detail/167/trevena-inc-announces-24-million-series-a-financing https://www.trevena.com/privacy-policy https://www.trevena.com/disclaimer https://www.trevena.com/terms-of-use https://www.trevena.com/sitemap https://www.trevena.com/accessibility-statement